Tuberculosis in resource poor countries

British Medical Journal

Volumn 334, Issue 7585, 2007, Pages 105-106

  Colebunders, Robert ^a   Apers, Ludwig ^a   Diettiens, Greet ^b   Worodria, William ^b  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b Infectious Diseases Institute   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID;

CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNODEFICIENCY; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MATHEMATICAL MODEL; MEDICAL EDUCATION; MEDICAL STAFF; MORTALITY; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SEROPREVALENCE; TUBERCULIN TEST; TUBERCULOSIS; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; DEVELOPING COUNTRIES; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; ISONIAZID; TUBERCULOSIS;

EID: 33846637706     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39092.388796.80     Document Type: Editorial

References (13)

1. Currie CS, Williams BG, Cheng RC, Dye C. Tuberculosis epidemics driven by HIV: is prevention better than cure? AIDS 2003;17:2501-8.
2. Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 2007;334:136-9. doi:10.1136/bmj.39000.486400.55.
3. Currie CS, Floyd K, Williams BG, Dye C. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health 2005;5:130.
4. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002;359:2059-64.
5. Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M. Reduced risk of TB among Brazilian patients with advanced HIV infection treated with HAART. Clin Infect Dis 2002;34:543-6.
6. Wanyenze R, Kamya M, Liechty CA, Ronald A, Guzman DJ, Wabwire-Mangen F, et al. HIV counseling and testing practices at an urban hospital in Kampala, Uganda. AIDS Behav 2006;10:361-7.
7. Levy NC, Miksad RA, Fein OT. From treatment to prevention: the interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South Africa. J Urban Health 2005;82:498-509.
8. Wambua N, Odhiambo J, Njoroge A, Chakaya JM, De Cock KM. Implementing measures to reduce the burden of HIV/TB in dually infected patients in a Nairobi slum [abstract]. 14th international conference on HIV/AIDS and sexually transmitted infections in Africa (ICASA). Abuja, Nigeria 2005:ThPoC00416.
9. WHO global tuberculosis programme/UNAIDS. Policy statement on preventive therapy against tuberculosis in people living with HIV. 1998; Document WHO/TB/98.255; UNAIDS/98.34. www.eldis.org/static/DOC7104.htm.
10. Golub JE, Saraceni V, Cavalcante S, Pacheco AG, King B, Moore RD, et al. Tuberculosis (TB) incidence by HAART and isoniazid prophylactic therapy (IPT) in HIV-infected patients in Rio de Janeiro, Brazil [abstract]. XVI international AIDS conference, 13-16 August 2006: MOPE0395.
11. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998;158:157-61.
12. John L, Baalwa J, Kalimugogo P, Nabankema E, Castelnuovo B, Muhindo G, Colebunders R, Kambugu A. Response to 'Does immune reconstitution promote active tuberculosis in patients receiving highly active antiretroviral therapy?' AIDS. 2005 Nov 18;19(17):2049-2050.
13. WHO. Briefing package. Integrated approaches to HIV care, ART and prevention: IMAI and IMCI tools. Geneva: WHO. www.who.int/3by5/publications/ documents/imai/en/.